retatrutide clinical trial safety Long-Term Safety: What Happens After 2 Years retatrutide clinical trial safety Retatrutide:

Synthetic GLP-1 and GIP agonists bind to their respective receptors and elicit the same response as the endogenous hormones would

Patients can have confidence in its consistent performance, knowing that it has been thoroughly tested and approved by the FDA

But they tell only part of the story

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)

Dose adjustment of Saxenda may be necessary if gastrointestinal symptoms are severe

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus and chronic weight management